` `

Too Early to Tell If J & J Vaccine is "100 Against Death"

Hind Khoudary Hind Khoudary
Health
21st February 2021
Too Early to Tell If J & J Vaccine is "100 Against Death"
The vaccine is 85% effective in preventing severe disease (Screenshot).

The Claim

The Johnson & Johnson vaccine's efficacy is "100% against death."

Emerging story

South Africa's Eye Witness News published an infographic on their website listing five facts people need to know about Johnson & Johnson’s vaccines.

EWN alleged that Johnson & Johnson’s COVID-19 efficacy against pre-existing variants is 66%, 85% against severe illness, and 100% against death.

Misbar’s Analysis

The results from an international phase 3 trial of Johnson & Johnson's single-dose COVID-19 vaccine show it is overall 66% effective in preventing moderate to severe symptoms of COVID-19.

The vaccine was 85% effective in preventing severe COVID-19 disease and 100% effective in preventing COVID-19-related hospitalizations and deaths.

According to Forbes, Johnson & Johnson's COVID-19 vaccine hasn't been approved by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).

FDA officials will then review the submitted data, compile a report, and submit the report to an independent vaccine advisory committee on February 26.

 The Eye Witness News linked J&J Ensemble as the source of information linked in the infographic. Our team didn't find the information mentioned in J&J Ensemble Studies.

 

The University of Minnesota corrected the headline and text of a story the shared the same claim.

While Johnson and Johnson's widespread, multi-continent study showed it to be 100% effective against death, the vaccine hasn't been approved. The approval process has yet to scrutinize this data. Thus, we have found that it is too early to confirm that the J&J vaccine will be 100% against death once released.

Misbar’s Classification

Suspicious

Misbar’s Sources

Read More

Most Read